Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity

Shah, Parag K; Narendran, Venkatapathy; Tawansy, K.A.; Raghuram, Aparna; Narendran, Kalpana

doi:10.4103/0301-4738.29505

Cited by 91 publications

(53 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…26 Pharmacotherapy may play an important role in the future. We hope that in the future, surgery can be avoided as far as possible in all cases of ROP, especially in bigger babies.…”

Section: Discussionmentioning

confidence: 99%

Anatomical and visual outcome of stages 4 and 5 retinopathy of prematurity

Shah

Narendran

et al. 2007

Eye

Self Cite

View full text Add to dashboard Cite

show abstract

“…26 Pharmacotherapy may play an important role in the future. We hope that in the future, surgery can be avoided as far as possible in all cases of ROP, especially in bigger babies.…”

Section: Discussionmentioning

confidence: 99%

Anatomical and visual outcome of stages 4 and 5 retinopathy of prematurity

Shah

Narendran

et al. 2007

Eye

Self Cite

View full text Add to dashboard Cite

show abstract

“…The findings of this study demonstrated that the neovascularization regressed in all groups no systemic complication was noted. [22] There are four studies in literature; that shows an intravitreal injection of bevacizumab was effective in regression of fibrovascular tissue in ROP patients.…”

Section: Discussionmentioning

confidence: 99%

Untitled

Kasiri

2017

AJP

View full text Add to dashboard Cite

Objective: Vascular endothelial growth factor (VEGF), originally known as vascular permeability factor with different important roles in triggering vasculogenesis and angiogenesis. This protein has a pivotal role in retinopathy of prematurity (ROP). This study aims to evaluate the efficacy of VEGF inhibitor with cryotherapy for zone II Stage 3 plus ROP. Methods: In a prospective controlled clinical trial was performed on 6 infants, 12 eyes with zone II Stage 3 plus ROP. There was neurological visual impairment (NVI) in one eye. Under general anesthesia after confirmation of staging, prep and drape done cryotherapy of avascular retina in two rows combined with intravitreal injection of 0.625 mg bevacizumab in 0.025 ml was performed, and in one eye with iris neovascularization 0.625 mg intracameral bevacizumab injected too, all eyes were examined in 3 days, 1 th , 4 th , and 12 th week after procedure. Results: Regression of NVI in 3 days and retinal neovascularization in 1 week period post operation. Conclusion: One session cryotherapy combined with intravitreal injection of 0.625 mg of bevacizumab can be effective in management of zone II Stage 3 plus ROP, more studies with more participants seems to be necessary.

show abstract

“…Following this experience, less surgical complications and bleeding were noticed in patients that received bevacizumab 3 days before pars plana vitrectomy. Some authors have gone further and broadened the indications for bevacizumab, like Shah et al 11 , who used it for retinopathy of prematurity in order to reduce anterior segment ischemia after aggressive laser treatment. They bravely broadened the indications for bevacizumab, but more studies have to be done on the issue to get satisfactory answers on the role and reasonable indications for the use of bevacizumab.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal bevacizumab for neovascular glaucoma

Derk

Mandić

Benčić

et al. 2007

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

SUMMARY The aim of the study was to assess short-term efficacy of intravitreal bevacizumab in a series of patients with neovascular glaucoma. Eleven patients with neovascular glaucoma and symptomatic elevation of intraocular pressure were treated with 1.25 mg/0.1 mL of bevacizumab. In three patients, intravitreal bevacizumab was administered preoperatively, one day before pars plana vitrectomy. Additional therapy was only performed if topical medication failed to result in satisfactory control of intraocular pressure. Patients were followed-up for a minimum of 8 weeks. In all study patients, intravitreal application of bevacizumab resulted in marked regression of iris neovascularization within the first three postoperative days. Appropriate control of intraocular pressure was achieved in seven patients, whereas four patients required additional therapy for intraocular pressure regulation. No side effects of intravitreal bevacizumab were recorded. Thus, intravitreal bevacizumab seems to be a potent adjunct in the management of neovascular glaucoma. Additional studies of bevacizumab long-term safety and efficacy are warranted.

show abstract

Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity

Cited by 91 publications

References 0 publications

Anatomical and visual outcome of stages 4 and 5 retinopathy of prematurity

Anatomical and visual outcome of stages 4 and 5 retinopathy of prematurity

Untitled

Intravitreal bevacizumab for neovascular glaucoma

Contact Info

Product

Resources

About